Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2018, Article ID 2061268, 7 pages
Research Article

PanCD44 Immunohistochemical Evaluation in Prostatectomies from Patients with Adenocarcinoma

1Pathology Department, Federal University of Ceará, Fortaleza, CE, Brazil
2Federal University of Ceará, Fortaleza, CE, Brazil
3Urology Department, Federal University of Ceará, Fortaleza, CE, Brazil
4Haroldo Juaçaba Hospital, Fortaleza, CE, Brazil

Correspondence should be addressed to Carlos Gustavo Hirth; rb.moc.htrih@solrac

Received 23 July 2017; Revised 3 December 2017; Accepted 15 January 2018; Published 26 February 2018

Academic Editor: Jeroen T. Buijs

Copyright © 2018 Carlos Gustavo Hirth et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


Introduction. CD44 has been proposed as a prognostic marker and a stem cell marker but studies in patients with prostate cancer have yielded inconsistent results. Patients and Methods. Patients submitted to radical prostatectomy between 2008 and 2013 at a university hospital were followed with biannual serum PSA tests to determine the biochemical recurrence (BR). Archived paraffin blocks with neoplastic and nonneoplastic tissue were evaluated immunohistochemically for a panCD44 and MYC. Results. Sixty-nine patients completed follow-up and were included. CD44 positivity was observed in inflammatory cells (42%), nonneoplastic epithelium (39.7%), and neoplastic tissue (12.3%). In nonneoplastic tissues staining was observed in basal and luminal cells with the morphology of terminally differentiated cells. In neoplastic tissues, CD44 negativity was correlated with higher Gleason scores (Rho = −0.204; ) and higher preoperative serum PSA levels when evaluated continuously (). CD44 expression was not associated with tumor stage (), surgical margin status (), or BR (), nor was there any association between CD44 and MYC expression in neoplastic tissue (). Conclusion. In the bulk of cells, the minority of cancer stem cells would not be detected by immunohistochemistry using panCD44. As a prognostic marker, its expression was weakly correlated with Gleason score and preoperative PSA level, but not with surgical margin status, tumor stage, or BR.